DRI Capital earmarks $1.45B for drug-royalty buys

DRI Capital has raised $1.45 billion to buy up drug royalties, aiming for everything from approved products to Phase III development candidates. The firm has a history of snagging royalty streams, and it now owns royalties on such drugs as Remicade, Enbrel and Soliris. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…